Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

November 21, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Glioblastoma
Interventions
DRUG

Temozolomide+Metformin

Low dose temozolomide+metformin for 24 weeks

DRUG

Temozolomide+Placebo

Low dose temozolomide+placebo for 24 weeks

Trial Locations (12)

10408

National Cancer Center Korea, Ilsan

13620

Seoul National University Bundang Hospital, Seongnam-si

16247

Saint Vincent's Hospital, Korea, Suwon

16499

Ajou University Hospital, Suwon

21431

Incheon St. Mary's Hospital, Incheon

58128

Chonnam National University Hwasun Hospital, Hwasun

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

05030

Konkuk University Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

Seoul St Mary's Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Saint Vincent's Hospital, Korea

OTHER

collaborator

Incheon St.Mary's Hospital

OTHER

collaborator

National Cancer Center, Korea

OTHER_GOV

collaborator

Konkuk University Hospital

OTHER

collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Seoul National University Hospital

OTHER

collaborator

Asan Medical Center

OTHER

collaborator

Ajou University School of Medicine

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Chonnam National University Hospital

OTHER

collaborator

Seoul St. Mary's Hospital

OTHER

lead

Yong-Kil Hong

OTHER